The American College of Rheumatology (ACR) praised the agency for recognizing the important role qualified clinical data registries (QCDRs) will play in the Merit-Based Incentive Payment System (MIPS) payment pathway, but expressed a number of...
24-Jun-2016 4:05 PM EDT Add to Favorites
Rheumatology Providers, FDA Leaders Discuss Biosimilar Policy Challenges and Opportunities at National Policy Briefing
Experts from the American College of Rheumatology (ACR), Food and Drug Administration (FDA), and other leading national healthcare groups spoke about the emerging biosimilars market, including key policy and regulatory questions for patients,...
20-Jun-2016 6:05 PM EDT Add to Favorites
The American College of Rheumatology has released an official statement on the MACRA proposed rule recently issued by CMS and its potential affects on the rheumatology community.
28-Apr-2016 1:05 PM EDT Add to Favorites
Rheumatology Community Responds to FDA Approval of Inflectra (Infliximab-dyyb), a Biosimilar to Remicade
The ACR has issued an official statement regarding the FDA's approval of Inflectra (infliximab-dyyb), a biosimilar to Remicade. Inflectra is the first biosimilar to receive approval in the U.S. for the treatment of rheumatic diseases, including...
6-Apr-2016 5:05 PM EDT Add to Favorites
The ACR supports the US Food and Drug Administration’s new draft guidance on biosimilars labeling and encourages additional measures that will help rheumatologists ensure the safety and efficacy of biosimilars for patients.
1-Apr-2016 4:05 PM EDT Add to Favorites
American College of Rheumatology Encourages Safe Adoption of Biosimilars During FDA Public Hearing on CT-P13, a Proposed Biosimilar for Infliximab (Remicade)
During a public meeting held Tuesday by the Food and Drug Administration (FDA)’s Arthritis Advisory Committee to review the license application of CT-P13, the American College of Rheumatology (ACR) provided recommendations for policy guidelines to...
10-Feb-2016 12:05 PM EST Add to Favorites
FDA Public Meeting on the Reauthorization of the Biosimilar User Fee Act (BsUFA) for Fiscal Years 2018 Through FY 2022
During a public meeting held Friday by the Food and Drug Administration (FDA), the American College of Rheumatology (ACR) expressed its support for reauthorization of the Biosimilar User Fee Act (BsUFA) and called for performance goals that...
11-Jan-2016 2:05 PM EST Add to Favorites
The American College of Rheumatology (ACR) released its 2015 Guideline for the Treatment of Rheumatoid Arthritis (RA) during the 2015 ACR/ARHP Annual Meeting in San Francisco. The guideline is designed for use by both rheumatologists and other...
10-Nov-2015 6:05 PM EST Add to Favorites
25-Jun-2012 10:55 AM EDT